All The Claims

1. A sorbent cartridge, comprising:
a first module configured to contain urease;
a second module fluidly connectable to the first module and downstream of the first module, the second module configured to contain a cation exchanger; and
a third module fluidly connectable to the second module and downstream of the second module, the third module configured to contain an anion exchanger.
2. The sorbent cartridge of claim 1, wherein the cation exchanger is zirconium phosphate contained in the second module and the anion exchanger is zirconium oxide contained in the third module.
3. The sorbent cartridge of claim 1, wherein the first module is single-use, the second module is multi-use, and the third module is multi-use.
4. The sorbent cartridge of claim 1, wherein the first module contains any one of activated carbon, ion exchange resin, alumina, urease, and combinations and mixtures thereof.
5. The sorbent cartridge of claim 1, wherein the first module has a first layer of activated carbon, a second layer of alumina and urease downstream of the first layer, and a third layer of activated carbon downstream of the second layer.
6. The sorbent cartridge of claim 5, wherein a layer of zirconium oxide is positioned downstream of the second layer and upstream of the third layer.
7. The sorbent cartridge of claim 1, wherein the first module is fluidly connectable to a dialysate flow path upstream of the first module, and the third module is fluidly connectable to a dialysate flow path downstream of the third module.
8. The sorbent cartridge of claim 2, wherein the zirconium oxide is present both upstream and downstream of the zirconium phosphate.
9. The sorbent cartridge of claim 8, wherein an amount of the zirconium oxide upstream of the zirconium phosphate is less than an amount of the zirconium oxide downstream of the zirconium phosphate.
10. The sorbent cartridge of claim 1, wherein the second module comprising the cation exchanger is multi-use, and the third module comprising the anion exchanger is multi-use.
11. The sorbent cartridge of claim 2, the second module having the proviso that zirconium oxide and zirconium phosphate are not contained together in the same module.
12. The sorbent cartridge of claim 2, wherein the second module does not comprise any other sorbent materials other than zirconium phosphate.
13. The sorbent cartridge of claim 1, further comprising a bypass flow path fluidly connecting a position upstream of the first module to the second module.
14. The sorbent cartridge of claim 1 wherein the first module has a first layer of activated carbon, and a second layer of alumina and urease downstream of the first layer, and the second module has a first layer of alumina, a second layer of activated carbon downstream of the first layer, and a third layer of zirconium phosphate downstream of the second layer.
15. A sorbent cartridge, comprising:
at least one module configured to contain a cation exchanger; and
at least one module configured to contain an anion exchanger, wherein the module configured to contain the anion exchanger is fluidly connectable to and downstream of the module configured to contain a cation exchanger.
16. The sorbent cartridge of claim 15, wherein the cation exchanger is zirconium phosphate and the anion exchanger is zirconium oxide.
17. The sorbent cartridge of claim 15, wherein the module configured to contain the cation exchanger and the module configured to contain the anion exchanger are multi-use.
18. The sorbent cartridge of claim 15, wherein the module configured to contain the cation exchanger and the module configured to contain the anion exchanger are detachable.
19. The sorbent cartridge of claim 16, further comprising at least a second module upstream of the module configured to contain zirconium phosphate, the second module configured to contain any one of activated carbon, alumina, urease, and combinations thereof.
20. The sorbent cartridge of claim 19, wherein the second module further comprises zirconium oxide.
21. The sorbent cartridge of claim 20, wherein an amount of the zirconium oxide the second module is less than an amount of the zirconium oxide downstream of the zirconium phosphate.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A storage-stable oil-in-water emulsified composition for ultraviolet protection comprising:
(a) Octocrylene;
(b) Bis ethylhexyloxyphenol methoxyphenyl triazine;
(c) Hexyl diethylaminohydroxyhenzoylbenzoate;
(d) 4-tert-butyl-4\u2032-methoxybenzoylmethane;
(e) Water soluble polymer;
(f) Water-swelling clay mineral;
(g) Oil component having IOB (ratio of Inorganic ValueOrganic Value) of 0.05 or more, wherein the oil component is selected from the group consisting of isononyl isononanoate, glyceryl 2-ethylhexanoate, cetyl 2-ethylhexanoate and diisopropyl sebacate;
(h) Higher fatty acid;
(i) Surfactant; and
(j) Water;
wherein
the octocrylene, bis ethylhexyloxyphenol methoxyphenyl triazine, hexyl diethylaminohydroxyhenzoylbenzoate and 4-tert-butyl-4\u2032-methoxybenzoylmethane are dissolved in the oil phase of the emulsion.
2. The oil-in-water emulsified composition of claim 1, wherein the blend ratio of said water-swelling clay mineral is 0.01-4 mass % of the total amount of the oil-in-water emulsified composition.
3. The oil-in-water emulsified composition of claim 1, wherein the ratio of said oil component having IOB of 0.05 or more in the oil phase is 20-75 mass %.
4. The oil-in-water emulsified composition of claim 1, wherein said water soluble polymer is a polysaccharide.
5. The oil-in-water emulsified composition of claim 1, wherein the total blend ratio of (a) Octocrylene, (b) Bis ethylhexyloxyphenol methoxyphenyl triazine, (c) Hexyl diethylaminohydroxybenzoylbenzoate, and (d) 4-tert-butyl-4\u2032-methoxybenzoylmethane is 5-30 mass % of the total amount of the oil-in-water emulsified composition.
6. The oil-in-water emulsified composition of claim 2, wherein the ratio of said oil component having IOB of 0.05 or more in the oil phase is 20-75 mass %.
7. The oil-in-water emulsified composition of claim 2, wherein said water soluble polymer is a polysaccharide.
8. The oil-in-water emulsified composition of claim 3, wherein said water soluble polymer is a polysaccharide.
9. The oil-in-water emulsified composition of claim 2, wherein the total blend ratio of (a) Octocrylene, (b) Bis ethylhexyloxyphenol methoxyphenyl triazine, (c) Hexyl diethylaminohydroxybenzoylbenzoate, and (d) 4-tert-butyl-4\u2032-methoxybenzoylmethane is 5-30 mass % of the total amount of the oil-in-water emulsified composition.
10. The oil-in-water emulsified composition of claim 3, wherein the total blend ratio of (a) Octocrylene, (b) Bis ethylhexyloxyphenol methoxyphenyl triazine, (e) Hexyl diethylaminohydroxybenzoylbenzoate, and (d) 4-tert-butyl-4\u2032-methoxybenzoylmethane is 5-30 mass % of the total amount of the oil-in-water emulsified composition.
11. The oil-in-water emulsified composition of claim 4, wherein the total blend ratio of (a) Octocrylene, (b) Bis ethylhexyloxyphenol methoxyphenyl triazine, (c) Hexyl diethylaminohydroxybenzoylbenzoate, and (d) 4-tert-butyl-4\u2032-methoxybenzoylmethane is 5-30 mass % of the total amount of the oil-in-water emulsified composition.
12. A storage-stable oil-in-water emulsified sunscreen cosmetic composition for ultraviolet protection, said composition comprising:
(a) Octocrylene;
(b) Bis ethylhexyloxyphenol methoxyphenyl triazine;
(c) Hexyl diethylaminohydroxyhenzoylbenzoate;
(d) 4-tert-butyl-4\u2032-methoxybenzoylmethane, wherein the total blend ratio of components (a), (b), (c) and (d) is 10-25 mass %;
(e) Water soluble polymer;
(f) Water-swelling clay mineral;
(g) Oil component having IOB of 0.05 or more, wherein the oil component is selected from the group consisting of isononyl isononanoate, glyceryl 2-ethylhexanoate, cetyl 2-ethylhexanoate and diisopropyl sebacate;
(h) Higher fatty acid;
(i) Surfactant; and
(j) Water;
wherein the octocrylene, bis ethylhexyloxyphenol methoxyphenyl triazine, hexyl diethylaminohydroxyhenzoylbenzoate and 4-tert-butyl-4\u2032-methoxybenzoylmethane are dissolved in the oil phase of the emulsion.
13. A storage-stable oil-in-water emulsified sunscreen cosmetic composition for ultraviolet protection, said composition comprising:
(a) Octocrylene;
(b) Bis ethylhexyloxyphenol methoxyphenyl triazine;
(c) Hexyl diethylaminohydroxyhenzoylbenzoate;
(d) 4-tert-butyl-4\u2032-methoxybenzoylmethane, wherein the total blend ratio of components (a), (b), (c) and (d) is 10-25 mass %;
(e) 0.01-5 mass % water soluble polymer;
(f) 0.01-4 mass % water-swelling clay mineral;
(g) 20-75 mass % oil component having IOB of 0.05 or more, wherein the oil component is selected from the group consisting of isononyl isononanoate, glyceryl 2-ethylhexanoate, cetyl 2-ethylhexanoate and diisopropyl sebacate;
(h) 0.01-10 mass % higher fatty acid;
(i) 0.01-10 mass % surfactant; and
(j) Water;
wherein all amounts are based on the total amount of the oil-in-water emulsified composition and wherein the octocrylene, bis ethylhexyloxyphenol methoxyphenyl triazine, hexyl diethylaminohydroxyhenzoylbenzoate and 4-tert-butyl-4\u2032-methoxybenzoylmethane are dissolved in the oil phase of the emulsion.
14. The oil-in-water emulsified composition of claim 13 wherein said water soluble polymer is a polysaccharide.

1. A method for recovering caprolactam from a rearrangement mixture of cyclohexanone oxime and sulfuric acid, comprising the steps of:
(a) neutralizing the rearrangement mixture with a base in a neutralization device to obtain a first crude lactam solution containing impurities above a standard value and a second crude lactam solution containing impurities below the standard value;
(b) feeding the first crude lactam solution into a temporary storage device, and feeding the second crude lactam solution into a buffering device;
(c1) feeding a first organic solvent and the first crude lactam solution in the temporary storage device into a temporary extraction device, allowing the first crude lactam solution to be in contact with the first organic solvent to perform batch extraction, so as to obtain a first lactam solution and a first impurity containing a minor amount of organic solvents;
(c2) feeding a second organic solvent and one of the second crude lactam solution in the buffering device and a combination of the second crude lactam solution and the first lactam solution continuously into an extraction device to perform continuous extraction, so as to obtain a second lactam solution and a second impurity containing a minor amount of organic solvents; and
(d) recovering caprolactam from the second lactam solution after the continuous extraction.
2. The method according to claim 1, wherein the step (d) further comprises a step of:
recovering caprolactam from the first lactam solution after the batch extraction, if the second organic solvent and the second crude lactam solution in the buffering device are continuously fed into the extraction device to perform the continuous extraction.
3. The method according to claim 2, wherein the first lactam solution is mixed with the second lactam solution in a ratio of 0.005:1 to 0.1:1 by volume, and the caprolactam is recovered.
4. The method according to claim 1, wherein the base is ammonium hydroxide.
5. The method according to claim 1, wherein the second crude lactam solution contains impurities below 500 ppm.
6. The method according to claim 1, wherein the second crude lactam solution contains impurities below 200 ppm.
7. The method according to claim 1, wherein the batch extraction is repeated one to three times.
8. The method according to claim 1, wherein the first organic solvent and the first crude lactam solution are mixed in a ratio of 1:1 to 3:1 by volume.
9. The method according to claim 1, wherein the first organic solvent and the second organic solvent are independently selected from the group consisting of aromatic hydrocarbons, hydrocarbons substituted with halogen atoms, and linear or cyclic aliphatic alcohols with 4 to 10 carbon atoms.
10. The method according to claim 1, wherein the first organic solvent and the second organic solvent are the same.
11. The method according to claim 1, wherein the first organic solvent and the second organic solvent are both benzene.
12. The method according to claim 1, wherein the second lactam solution contains 15 to 30 wt % caprolactam.
13. The method according to claim 1, wherein the first lactam solution contains 2 to 25 wt % caprolactam.
14. The method according to claim 1, further comprising a step of stripping by steaming the first impurity fed from the temporary extraction device and the second impurity fed from the extraction device.
15. The method according to claim 1, wherein after the first crude lactam solution is extracted with the first organic solvent, the first crude lactam solution stands to separate out a mixture containing sulfates and a minor amount of lactam.
16. The method according to claim 15, wherein the mixture is fed into the neutralization device again to repeat the neutralization of step (a).
17. The method according to claim 1, wherein step (a) further comprises a step of detecting the amounts of the impurities of the first and second crude lactam solutions.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A medical device for treatment of a disease comprising:
a non-invasive brain stimulator operative to selectively stimulate at least one region of a brain of a patient, which at least one region is associated with said disease; and
a cognitive stimulator operative to stimulate at least one cognitive feature in said patient, which said at least one cognitive feature is associated with said disease.
2. A medical device according to claim 1 and wherein said medical device also comprises an analyzer operative to modulate operation of said medical device based at least in part on comparison of a measurement of a property in a patient to a norm of said property, which property is one of the following items: a localized brain feature and a cognitive feature.
3. A medical device according to claim 1 and wherein said medical device also comprises a feedback modulator operative to modulate operation of said medical device based at least in part on detection and analysis of alteration of a property following operation of said medical device, which property is one of the following items: a localized brain feature and a cognitive feature.
4. A method of therapy for a disease, the method comprising:
stimulating at least one region of a brain of a patient, which at least one region is associated with said disease; and
stimulating at least one cognitive feature in said patient, which said at least one cognitive feature is associated with said disease.
5. A method of therapy for a disease according to claim 4 and wherein said method also comprises:
comparing a measurement of a property in property in a patient to a norm of said property, which property is one of the following items: a localized brain feature and a cognitive feature;
and wherein said comparing modulates at least one of the following: said stimulating at least one region of a brain of a patient and said stimulating at least one cognitive feature in said patient.
6. A method of therapy for a disease according to claim 4 and wherein said method also comprises:
analyzing alteration of a property following operation of said medical device, which property is one of the following items: a localized brain feature and a cognitive feature;
and wherein said analyzing modulates at least one of the following: said stimulating at least one region of a brain of a patient and said stimulating at least one cognitive feature in said patient.
7. A medical device for treatment of a disease comprising an electromagnetic stimulator and a laser stimulator and operative to induce a magnetic photo-electric stimulation which selectively stimulates at least one region of a brain of a patient, which at least one region is associated with said disease.
8. A method of therapy for a disease, the method comprising:
electromagnetically stimulating at least one region of a brain of a patient, which at least one region is associated with said disease; and
laser stimulating said at least one region of a brain of a patient by means of at least one laser beam;
and wherein said electromagnetically stimulating and said laser stimulating cause a magnetic photo-electric stimulation.
9. A medical device for treatment of a disease comprising:
a first stimulus generator, operative to induce selective stimulation of a first region of a brain of a patient; and
a second stimulus generator, operative to induce selective stimulation of a second region of said brain of said patient, which second region of said brain of said patient is different from said first region of said brain of said patient;
and wherein a third region of said brain of said patient is comprised in said first region of said brain of said patient and in said first region of said brain of said patient, and is associated with said disease.
10. A method of therapy for a disease, the method comprising:
stimulating a first region of a brain of a patient by means of a first stimulus generator;
stimulating a second region of said brain of said patient, which second region of said brain of said patient is different from said first region of said brain of said patient, by means of a second stimulus generator;
and wherein a third region of said brain of said patient is comprised in said first region of said brain of said patient and in said first region of said brain of said patient, and is associated with said disease.